Jasper E. Neggers, Ph.D.
About Jasper E. Neggers, Ph.D.
Jasper E. Neggers, Ph.D., is a Co-Founder and Chief Scientific Officer at Promakhos Therapeutics, where he has contributed to drug discovery and development since 2021. He holds a Ph.D. in Biomedical Sciences from KU Leuven and has held various research and teaching positions at prestigious institutions including Harvard Medical School and the Broad Institute.
Work at Promakhos Therapeutics
Jasper E. Neggers, Ph.D. serves as Co-Founder, Chief Scientific Officer, and Secretary at Promakhos Therapeutics. He has held this position since 2021, contributing to the company's mission in drug discovery and development. His role involves overseeing scientific strategy and operations, leveraging his extensive background in biomedical sciences to drive innovative research initiatives.
Education and Expertise
Jasper E. Neggers completed his Doctor of Philosophy (PhD) in Biomedical Sciences at KU Leuven from 2013 to 2018. He also holds a Master of Science (MSc) in Biomedical Sciences from the same institution, achieved between 2011 and 2013. His academic journey began with a Bachelor of Science (BSc) in Biomedical Sciences, completed from 2008 to 2011. Additionally, he studied Oncology and Cancer Biology as a Postdoctoral Research Fellow at Harvard Medical School from 2018 to 2021.
Background
Jasper E. Neggers grew up in the Netherlands and pursued his education in biomedical sciences at KU Leuven. He transitioned to the United States as a postdoctoral fellow, working at prestigious institutions such as the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard. His research background encompasses microbiology, immunology, cell biology, and functional genomics.
Achievements
Jasper E. Neggers has made significant contributions to cancer research, including co-developing phenotypic drug discovery campaigns and inventing a new CRISPR method for drug target deconvolution. He has secured funding as Principal Investigator for both the NIDDK Phase 1 SBIR Grant and the Propel A Cure For Crohn's disease 2024 Research Award. His work has led to the identification of new therapeutic targets and metabolic vulnerabilities in cancer.
Professional Experience
Prior to his current role, Jasper E. Neggers held various research positions, including a Damon Runyon Postdoctoral Research Fellow at the Damon Runyon Cancer Research Foundation from 2019 to 2021. He also worked as a Visiting Research Fellow at the Broad Institute of MIT and Harvard and as a Postdoctoral Research Fellow at both Harvard Medical School and Dana-Farber Cancer Institute. His experience includes leading pharmacokinetic/dynamic studies and participating in programs such as the Harvard LLX GEO program and Y Combinator S21.